Welcome to our dedicated page for Adocia news (Ticker: ADOCY), a resource for investors and traders seeking the latest updates and insights on Adocia stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adocia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adocia's position in the market.
Adocia (Euronext Paris: ADOC) announced a patent filing for an innovative oral delivery technology of peptides, aimed at transforming diabetes treatment. The technology demonstrated promising in vivo results for a GLP-1 receptor agonist, and a first-in-human clinical study is planned for 2022 to establish proof of concept. This new platform could enhance patient compliance and broaden therapeutic applications across various peptides and proteins.
Adocia, a clinical-stage biopharmaceutical company, reported its Q3 2021 financial results and announced a €7 million financing completion. The cash position was €14.3 million as of September 30, 2021, down from €28.1 million at the end of 2020. Licensing revenues increased to €106,000 from €59,000 year-over-year, totaling €529,000 for the quarter. The financing is expected to enhance project development for innovative treatments, particularly short-acting hormones for obesity. The share capital post-financing will reach approximately €713,752.10.
Adocia (Euronext Paris: ADOC) announced the initiation of a Phase 3 clinical trial for its BioChaperone® Lispro, targeting the Chinese diabetes market valued at $1.4 billion. This pivotal trial, which will enroll over 1,300 diabetes patients, aims to demonstrate the non-inferiority of BC Lispro compared to Humalog on HbA1c reduction. Successful enrollment of the first patient will trigger a milestone payment. Adocia has the potential to earn up to $45 million from its partnership with Tonghua Dongbao, including royalties on future sales.
Adocia, a clinical-stage biopharmaceutical company focused on diabetes treatments, announced an oral presentation for M1Pram (ADO09) at the 57th Annual Meeting of the European Association for the Study of Diabetes from September 27 to October 1, 2021. The presentation will detail Phase I clinical trial results showing that M1Pram, a combination of pramlintide and insulin A21G, improves post-prandial glucose and body weight in type 1 diabetes patients compared to insulin aspart. The session is scheduled for September 29, 2021.
Adocia (Euronext Paris: ADOC) announced that CEO Gérard Soula will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation format includes a corporate presentation and one-on-one meetings, starting on September 13 at 7:00 AM EDT. Adocia specializes in innovative treatments for diabetes and metabolic diseases, featuring a robust clinical pipeline with six products and advanced technology like the BioChaperone® platform. The conference allows investors to engage in virtual meetings with management.
Adocia (ADOC) reported its financial results for the first half of 2021, revealing a net loss of €10.6 million, improved from €11.9 million in 2020. Revenue decreased to €0.4 million, primarily from licensing agreements with Tonghua Dongbao Pharmaceuticals. Operating expenses fell to €12.2 million due to reduced clinical and preclinical costs. The cash position is €20.7 million, down from €28.1 million at the end of 2020. The company is advancing in diabetes treatments, with ongoing clinical trials and promising developments in cell therapy and obesity.
FAQ
What is the market cap of Adocia (ADOCY)?
